UnknownNot Applicable

Quality of Life in Patients Who Have Undergone Previous Treatment for Primitive Neuroectodermal Tumors

Ireland, United KingdomStarted 2002-06

Plain-language summary

RATIONALE: Questionnaires that measure quality of life may improve the ability to plan treatment for patients with primitive neuroectodermal tumors. PURPOSE: This phase III trial is studying quality of life in patients who have undergone previous treatment for primitive neuroectodermal tumors.

Who can participate

Age range3 Years – 24 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

DISEASE CHARACTERISTICS: * Surviving primitive neuroectodermal tumor (PNET) patients previously enrolled in International Pediatric Oncology Society (SIOP) 2 or 3 phase III treatment trials * Surviving PNET patients eligible for and treated according to PNET 3 protocol but not randomized * No metastatic disease at time of allocation to treatment * No current progressive disease PATIENT CHARACTERISTICS: * No patient deemed unsuitable for this study by treating clinician PRIOR CONCURRENT THERAPY: * Not specified

What they're measuring

Quality of life (QOL) as measured by QOL questionnaire

Trial details

NCT IDNCT00278239

SponsorChildren's Cancer and Leukaemia Group

Sponsor typeOTHER

Study typeOBSERVATIONAL

View on ClinicalTrials.gov More Brain and Central Nervous System Tumors trials